{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:07:16Z","timestamp":1781280436534,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology Case Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.eucr.2026.103347","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:55:18Z","timestamp":1768377318000},"page":"103347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clonal selection of pre-existing neuroendocrine component in prostate cancer during androgen receptor signaling inhibitor therapy: A case report"],"prefix":"10.1016","volume":"65","author":[{"given":"Haruka","family":"Kubota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4380-9294","authenticated-orcid":false,"given":"Toshiki","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadzki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Uematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Kamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 3","key":"10.1016\/j.eucr.2026.103347_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2022.05.007","article-title":"Molecular mechanisms underlying the development of neuroendocrine prostate cancer","volume":"86","author":"Liu","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10.1016\/j.eucr.2026.103347_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","article-title":"Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy","volume":"81","author":"Cheng","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.eucr.2026.103347_bib3","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s42003-020-01476-1","article-title":"Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer","volume":"3","author":"Dong","year":"2020","journal-title":"Commun Biol"},{"issue":"16","key":"10.1016\/j.eucr.2026.103347_bib4","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1158\/0008-5472.CAN-18-0610","article-title":"Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations","volume":"78","author":"Sowalsky","year":"2018","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.eucr.2026.103347_bib5","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/pros.24588","article-title":"Real-world analysis of metastatic prostate cancer demonstrates increased frequency of PSA-imaging discordance with visceral metastases and upfront ARAT\/docetaxel therapy","volume":"83","author":"Hara","year":"2023","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.eucr.2026.103347_bib6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.euo.2020.07.001","article-title":"Patterns of cancer progression of metastatic hormone-sensitive prostate cancer in the ECOG3805 CHAARTED trial","volume":"3","author":"Bryce","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.eucr.2026.103347_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/aja202494","article-title":"Androgen receptor inhibitors in treating prostate cancer","volume":"27","author":"Cole","year":"2025","journal-title":"Asian J Androl"},{"issue":"1","key":"10.1016\/j.eucr.2026.103347_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1442-2042.2008.02175.x","article-title":"Neuroendocrine differentiation in the progression of prostate cancer","volume":"16","author":"Komiya","year":"2009","journal-title":"Int J Urol"},{"issue":"12","key":"10.1016\/j.eucr.2026.103347_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123792","article-title":"Neuroendocrine and aggressive-variant prostate cancer","volume":"12","author":"Spetsieris","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.eucr.2026.103347_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and biological features of neuroendocrine prostate cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"10.1016\/j.eucr.2026.103347_bib11","doi-asserted-by":"crossref","first-page":"T67","DOI":"10.1530\/ERC-21-0140","article-title":"Therapy considerations in neuroendocrine prostate cancer: what next?","volume":"28","author":"Beltran","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.eucr.2026.103347_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41420-019-0218-y","article-title":"Targeting Wnt\/EZH2\/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer","volume":"5","author":"Shan","year":"2019","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.eucr.2026.103347_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.926585","article-title":"The role of epigenetic change in therapy-induced neuroendocrine prostate cancer lineage plasticity","volume":"13","author":"Storck","year":"2022","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.eucr.2026.103347_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.695","article-title":"The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): a new targeted therapy of NEPC","volume":"12","author":"Lee","year":"2022","journal-title":"Clin Transl Med"},{"issue":"37","key":"10.1016\/j.eucr.2026.103347_bib15","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1038\/s41388-022-02437-0","article-title":"Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer","volume":"41","author":"Wang","year":"2022","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.eucr.2026.103347_bib16","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1158\/0008-5472.CAN-17-3677","article-title":"Heterochromatin protein 1\u03b1 mediates development and aggressiveness of neuroendocrine prostate cancer","volume":"78","author":"Ci","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.eucr.2026.103347_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-92552-x","article-title":"MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer","volume":"11","author":"Hsu","year":"2021","journal-title":"Sci Rep"}],"container-title":["Urology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442026000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442026000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:43:23Z","timestamp":1781279003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214442026000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":17,"alternative-id":["S2214442026000100"],"URL":"https:\/\/doi.org\/10.1016\/j.eucr.2026.103347","relation":{},"ISSN":["2214-4420"],"issn-type":[{"value":"2214-4420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clonal selection of pre-existing neuroendocrine component in prostate cancer during androgen receptor signaling inhibitor therapy: A case report","name":"articletitle","label":"Article Title"},{"value":"Urology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eucr.2026.103347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103347"}}